Association Between Peripheral Blood Monocyte Count and Mucosal Healing in Japanese Patients With Ulcerative Colitis

Shinya Furukawa, MD, PhD1, Yoshio Ikeda, MD, PhD2, Sen Yagi, MD, PhD3, Teruki Miyake, MD, PhD4, Kana Shiraishi, MD4, Kazuhiro Tange, MD5, Yu Hashimoto, MD6, Kenichirou Mori, MD, PhD6, Tomoyuki Ninomiya, MD, PhD6, Seiyuu Suzuki, MD, PhD7, Naozumi Shibata, MD, PhD8, Hidehiro Murakami, MD, PhD9, Katsuhisa Ohashi, MD, PhD9, Aki Hasebe, MD, PhD10, Hideomi Tomida, MD, PhD10, Yasunori Yamamoto, MD, PhD10, Eiji Takeshita, MD, PhD10 and Yoichi Hiasa, MD, PhD4

INTRODUCTION: Monocytes play an important role in innate immunity. Some epidemiological evidence indicates an association between peripheral blood monocytes and ulcerative colitis (UC). The association between peripheral blood monocytes and mucosal healing (MH), however, remains unclear. We evaluated this issue in patients with UC.

METHODS: Study subjects consisted of 272 Japanese patients with UC. Monocyte counts were taken in the morning after overnight fasting. Monocyte count was divided into tertiles based on the distribution of values among all study subjects. Information on clinical remission was obtained from medical records. MH was assessed using the Mayo endoscopic subscore.

RESULTS: The mean monocyte count was 360.1 ± 155.3/mm³. Rates of clinical remission, MH, and complete MH were 61.0%, 66.2%, and 27.9%, respectively. High monocyte count was significantly inversely associated with clinical remission, MH, and complete MH (adjusted odds ratio [OR] 0.45 [95% confidence interval [CI]: 0.23–0.89], OR 0.45 [95% CI: 0.23–0.89], and OR 0.48 [95% CI: 0.23–0.97], respectively). Patients were also classified according to C-reactive protein (CRP) levels; in the low CRP group (<0.1 mg/dL), high monocyte count was independently inversely associated with complete MH but not with clinical remission or MH (OR 0.33 [95% CI: 0.10–0.92], P for trend = 0.027). In the high CRP group, there was no association between monocyte count and clinical outcomes.

DISCUSSION: Our findings suggest that peripheral blood monocyte count can be used as a serum supplemental marker for MH in UC patients with low CRP levels.

Clinical and Translational Gastroenterology 2021;12:e00429. https://doi.org/10.14309/ctg.0000000000000429

INTRODUCTION
The clinical course of ulcerative colitis (UC) is characterized by repeated relapses and remissions (1). Mucosal healing (MH) is inversely associated with clinical relapse, rates of hospitalization and surgery, and incidence of colorectal cancer (2–7); accordingly, MH is the therapeutic goal for UC. As the number of patients with UC increases in Asian countries and remains high in Western countries (8), the unmet need for a rapid, repeatable, cost-effective, and clinically useful serum biomarker for MH, a necessary key to achieving long-term MH in patients with UC, grows more urgent worldwide (9).

Peripheral blood leukocyte subtypes including monocytes can be monitored at clinical visits; such data are routinely available. Dysregulation of mucosal innate immunity seems to be a key factor in the pathogenesis of UC (10), and monocytes play an important role in innate immunity. There are several sources of evidence regarding the association between peripheral blood monocyte count and disease activity in patients with UC (11–15).
An association between peripheral blood monocyte count and MH in patients with UC, however, is yet to be confirmed.

In general, serological biomarkers for intestinal inflammation have lower sensitivity and less specificity in patients with UC compared with those in other patients (16). We have previously reported that, in patients with UC, the expected inverse association between serum globulin level and MH was found only in a low-C-reactive protein (CRP) group and not in a high-CRP group (17). Among patients with colorectal cancer, the combination of CRP and monocyte count is a useful marker for prognosis (18). Thus, we hypothesize that the combination of CRP and peripheral blood monocyte count might be a more useful prognostic marker for clinical outcomes in patients with UC as well. In this study, we explored the association between peripheral blood monocyte count and clinical outcomes including MH after CRP stratification in Japanese patients with UC.

**METHODS**

**Study population**

Study subjects in the baseline survey consisted of 387 Japanese patients with UC who visited the Department of Gastroenterology and Metabolism at the Ehime University Graduate School of Medicine or several affiliated hospitals in Ehime Prefecture. All patients who were able to consent to the study and respond to the self-administered questionnaire were considered as candidates for inclusion. The final analysis sample in this study consisted of 272 patients because 115 patients were excluded because of incomplete data. All patients had been diagnosed with UC based on radiological, endoscopic, histological, and clinical criteria. This study was conducted in accordance with the Declaration of Helsinki, and the study protocol was approved by the institutional review board of the Ehime University Graduate School of Medicine (#1505011). Trained staff obtained written informed consent from all enrolled patients. This study cohort was registered during the period 2015–2019.

**Measurements**

Information on CRP, peripheral blood monocyte count, endoscopic findings, disease extent, clinical remission, and the use of medication for UC was obtained from medical records. Other variables were reported in a self-administered paper-and-pencil questionnaire. Blood samples were taken in the morning after overnight fasting. A well-trained laboratory medical technologist measured each patient’s monocyte count using a flow cytometer. Height was measured to the nearest millimeter using a stadiometer with the patient standing completely erect. Height was measured to the nearest millimeter using a stadiometer with the patient standing completely erect. Weight was measured in light clothing. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Blood examination was performed when a colonoscopy was booked or when the colonoscopy examination was performed, and up to 2 months may have passed between the blood examination and the colonoscopy.

**Assessment of clinical remission, endoscopic activity, and MH.**

Clinical remission was defined as no rectal bleeding and stool frequency < 3 times per day.

MH was assessed using the Mayo endoscopic subscore (MES) (19). In this study, MH and complete MH were defined as categories 0 and 0–1, respectively. All endoscopic findings were interpreted by only 1 endoscopy specialist, who was blinded to CRP and peripheral blood monocyte count.

**Statistical analysis.** Monocyte count was divided into tertiles according to the distribution of this value among all study subjects as follows: (i) low monocyte count, < 281/mm³ (reference category); (ii) moderate monocyte count, 281–391/mm³; and (iii) high monocyte count, ≥ 391/mm³. CRP values were classified as either low (<0.1 mg/dL) or high (≥0.1 mg/dL). Crude odds ratios (ORs) and their 95% confidence intervals (CIs) for clinical remission, MH, and complete MH in relation to peripheral blood monocyte count were estimated using logistic regression analysis. Multiple logistic regression analyses were used to adjust for potential confounding factors. Age, sex, BMI, disease extent (proctitis/nonproctitis), prednisolone use, and antitumor necrosis factor (TNF)-α monoclonal antibody preparation use were selected a priori as potential confounding factors. All statistical analyses were mainly performed using SAS software package, version 9.4 (SAS Institute, Cary, NC). A receiver operating characteristic (ROC) curve was generated, and the area under the curve was calculated to measure the utility of monocyte count in indicating MH. JMP 14.2 (SAS Institute) was used to analyze the ROC curve and to identify the cutoff value, specificity, and sensitivity of peripheral blood monocyte count. All probability values for statistical tests were 2-tailed, and $P < 0.05$ was considered statistically significant.

**RESULTS**

**Cohort characteristics**

Table 1 summarizes the characteristics of the 272 study patients. The mean age, mean BMI, and proportion of male subjects were 51.0 years, 22.85, and 57.7%, respectively. The proportions of subjects treated with 5-aminosalicylates, prednisolone, anti-TNF-α monoclonal antibody preparations, and azathioprine were 91.2%, 19.9%, 5.5%, and 16.5%, respectively. The mean

| Table 1. Clinical characteristics of 272 study participants |
| --- |
| Variable | n (%) |
| Age, yr, mean ± SD | 51.0 ± 16.2 |
| Male (%) | 157 (57.7) |
| BMI | 22.85 ± 4.59 |
| Disease extent (pancolitis/left-sided/proctitis/others) | 115/71/79/7 |
| Medication |  |
| 5-aminosalicylates (%) | 248 (91.2) |
| Prednisolone (%) | 54 (19.9) |
| TNF-α monoclonal antibody (%) | 15 (5.5) |
| Azathioprine (%) | 45 (16.5) |
| Clinical remission, % | 166 (61.0) |
| MES, mean ± SD | 1.12 ± 0.89 |
| Partial MH (MES ≤ 1) (%) | 180 (66.2) |
| MH (MES < 1) (%) | 76 (27.9) |
| Monocyte counts/mm³, mean ± SD | 360.1 ± 155.3 |
| CRP, mg/dL, median ± IQR | 0.099 ± 0.21 |
| BMI, body mass index; CRP, C-reactive protein; IQR, interquartile range; MES, Mayo endoscopic subscore; MH, mucosal healing; TNF, tumor necrosis factor. |
monocyte count was 360.1 ± 155.3/mm³. Peripheral blood monocyte count was significantly higher in patients treated with prednisolone than in patients not treated with prednisolone (436.0 ± 197.4/mm³ vs 341.4 ± 137.2/mm³, P = 0.001) but did not differ between patients treated with and without any other medications.

**Association between peripheral blood monocyte count and clinical outcomes**

Table 2 summarizes the association between peripheral blood monocyte count and clinical remission, MH, and complete MH. High monocyte count was inversely associated with clinical remission, MH, and complete MH (crude OR 0.36 [95% CI: 0.19–0.66], crude OR 0.37 [95% CI: 0.19–0.70], and crude OR 0.39 [95% CI: 0.20–0.75], respectively). Even after adjustment for confounding factors, high monocyte count was independently inversely associated with clinical remission, MH, and complete MH (clinical remission: adjusted OR 0.45 [95% CI: 0.23–0.89], P for trend = 0.036, MH: adjusted OR 0.45 [95% CI: 0.23–0.89], P for trend = 0.023, and complete MH: adjusted OR 0.48 [95% CI: 0.23–0.97], P for trend = 0.021).

**Association between peripheral blood monocyte count and MH after CRP stratification**

Table 3 summarizes the crude and adjusted ORs and 95% CIs for clinical outcomes in relation to peripheral blood monocyte count after CRP stratification. In the low CRP group (CRP < 0.1 mg/dL), an inverse association between monocyte count and clinical outcome was found in the crude analysis. After adjustment, however, high monocyte count was independently inversely associated with complete MH (adjusted OR 0.33 [95% CI: 0.13–0.92], P for trend = 0.027), but not with clinical remission or MH. In the high CRP group (CRP ≥ 0.1 mg/dL), there was no association between peripheral blood monocyte count and clinical outcomes. In the low CRP group, the ROC curve of the peripheral blood monocyte count for identifying complete MH had an area under the curve of 0.614 (Figure 1).

**DISCUSSION**

This study demonstrates that peripheral blood monocyte count is independently inversely associated with clinical remission and MH among patients with UC. To the best of our knowledge, this is the first study to show an inverse association between peripheral blood monocyte count and MH in patients with UC. In the low CRP group, high monocyte count was independently inversely associated with MH, but not partial MH or clinical remission. In UC patients with low CRP, therefore, peripheral blood monocyte count might serve as a supplemental blood marker for MH.

Several previous studies have reported an association between peripheral blood monocyte count and UC. In a US case–control study of 260 subjects including 110 UC patients, as mentioned earlier, the monocyte count was higher in patients with active-stage UC than in those with remission-stage UC (11). In an Egyptian study of patients with UC, monocyte count was higher among patients in active stage (MES ≥2) than among those in remission stage (MES 0–1) (13). In a UK study of 139 subjects (83 patients with IBD, 37 healthy controls, and 17 disease controls), absolute peripheral blood monocyte count was higher in patients with UC than in healthy controls and was positively associated with disease severity of UC (12). In a US cohort study of 1,290 patients with IBD including 463 patients with UC (14), monocytosis was positively associated with CRP, anemia, disease severity, hospitalization, surgery, emergency department visits, and annual financial health-care costs. In addition, quality of life was worse in UC patients with concomitant monocytosis than in UC patients without it. The findings of this study are consistent with

### Table 2. Crude and adjusted ORs and 95% CIs for the associations between monocyte counts and clinical outcomes

| Variable | Prevalence (%) | Crude OR (95% CI) | Adjusted OR (95% CI) |
|----------|----------------|-------------------|---------------------|
| Clinical remission | 65/90 (72.2) | 1.00 | 1.00 |
| Low (monocyte count <281/mm³) | 57/91 (62.6) | 0.65 (0.34–1.20) | 0.70 (0.36–1.35) |
| Moderate (281 ≤ monocyte count <391/mm³) | 44/91 (48.4) | 0.36 (0.19–0.66) | 0.45 (0.23–0.89) |
| High (391/mm³ ≤ monocyte count) | 57/91 (62.6) | 0.65 (0.34–1.20) | 0.70 (0.36–1.35) |
| P for trend | | | 0.036 |
| Partial MH (MES ≤1) | 69/90 (76.7) | 1.00 | 1.00 |
| Low (monocyte count <281/mm³) | 61/91 (67.0) | 0.62 (0.32–1.19) | 0.69 (0.35–1.36) |
| Moderate (281 ≤ monocyte count <391/mm³) | 50/91 (55.0) | 0.37 (0.19–0.70) | 0.45 (0.23–0.89) |
| High (391/mm³ ≤ monocyte count) | 50/91 (55.0) | 0.37 (0.19–0.70) | 0.45 (0.23–0.89) |
| P for trend | | | 0.023 |
| MH (MES < 1) | 35/90 (38.9) | 1.00 | 1.00 |
| Low (monocyte count <281/mm³) | 23/91 (25.3) | 0.53 (0.28–0.998) | 0.57 (0.29–1.10) |
| Moderate (281 ≤ monocyte count <391/mm³) | 18/91 (19.8) | 0.39 (0.20–0.75) | 0.48 (0.23–0.97) |
| High (391/mm³ ≤ monocyte count) | | | 0.021 |

ORs were adjusted for age, sex, body mass index, use of prednisolone, use of tumor necrosis factor-α monoclonal antibody, and disease extent. CI, confidence interval; MES, Mayo endoscopic subscore; MH, mucosal healing; OR, odds ratio.
these previous studies, revealing various associations between peripheral blood monocyte count and clinical outcomes.

By contrast, a Chinese study of 217 patients with IBD (76 UC and 141 Crohn’s disease) found that peripheral blood monocyte count did not significantly differ between active-stage and inactive-stage IBD, regardless of Clostridioides difficile infection, although a positive relationship between peripheral blood monocyte count and CRP was observed in patients with active UC (15). The discrepancy between this finding and our study results may be explained, partly, by differences in sample size, study design, assessment of disease activity, medication use, and patients’ age.

Although we have shown a link between peripheral blood monocyte count and MH in patients with UC, the underlying mechanism linking peripheral blood monocyte count and MH remains unclear. Persistent activation of monocytes and dysregulation of innate immune responses are involved in the development of UC (20). Proinflammatory cytokines and chemokines can generate monocytes and recruit them to areas of inflammation. Peripheral blood monocyte and macrophage counts in the blood are linked to those in areas of inflammation (21). Excessive numbers of peripheral blood monocytes can impair healing in an ischemic heart disease model (21,22).

### Table 3. Crude and adjusted ORs and 95% CIs for the associations between monocyte count and clinical outcomes according to patient CRP level

| Variable                  | Prevalence (%) | Crude OR (95% CI)       | Adjusted OR (95% CI) |
|---------------------------|----------------|-------------------------|----------------------|
| **CRP < 0.1 mg/dL (n = 147)** |                |                         |                      |
| Clinical remission       |                |                         |                      |
| Low (monocyte count < 281/mm$^3$) | 44/61 (72.1)   | 1.00                    | 1.00                 |
| Moderate (281 ≤ monocyte count < 391/mm$^3$) | 33/50 (66.0)   | 0.75 (0.33–1.69)        | 0.82 (0.34–1.97)    |
| High (391/mm$^3$ ≤ monocyte count) | 18/36 (50.0)   | 0.39 (0.16–0.91)        | 0.53 (0.20–1.40)    |
| $P$ for trend             |                |                         | 0.21                 |
| Partial MH (MES ≤ 1)     |                |                         |                      |
| Low (monocyte count <281/mm$^3$) | 50/61 (82.0)   | 1.00                    | 1.00                 |
| Moderate (281 ≤ monocyte count < 391/mm$^3$) | 34/50 (68.0)   | 0.47 (0.19–1.12)        | 0.48 (0.19–1.19)    |
| High (391/mm$^3$ ≤ monocyte count) | 23/36 (63.9)   | 0.39 (0.15–0.996)       | 0.52 (0.19–1.43)    |
| $P$ for trend             |                |                         | 0.17                 |
| MH (MES < 1)              |                |                         |                      |
| Low (monocyte count <281/mm$^3$) | 26/61 (42.6)   | 1.00                    | 1.00                 |
| Moderate (281 ≤ monocyte count < 391/mm$^3$) | 13/50 (26.0)   | 0.47 (0.21–1.05)        | 0.50 (0.21–1.15)    |
| High (391/mm$^3$ ≤ monocyte count) | 6/36 (16.7)    | 0.27 (0.09–0.71)        | 0.33 (0.10–0.92)    |
| $P$ for trend             |                |                         | 0.27                 |
| **CRP ≥ 0.1 mg/dL (n = 125)** |                |                         |                      |
| Clinical remission       |                |                         |                      |
| Low (monocyte count <281/mm$^3$) | 21/29 (72.4)   | 1.00                    | 1.00                 |
| Moderate (281 ≤ monocyte count < 391/mm$^3$) | 24/41 (58.5)   | 0.54 (0.19–1.47)        | 0.65 (0.21–1.94)    |
| High (391/mm$^3$ ≤ monocyte count) | 25/55 (47.2)   | 0.34 (0.12–0.88)        | 0.44 (0.15–1.24)    |
| $P$ for trend             |                |                         | 0.12                 |
| Partial MH (MES ≤ 1)     |                |                         |                      |
| Low (monocyte count <281/mm$^3$) | 19/29 (65.5)   | 1.00                    | 1.00                 |
| Moderate (281 ≤ monocyte count < 391/mm$^3$) | 27/41 (65.9)   | 1.02 (0.37–2.76)        | 1.18 (0.39–3.62)    |
| High (391/mm$^3$ ≤ monocyte count) | 27/55 (49.1)   | 0.51 (0.20–1.27)        | 0.62 (0.21–1.73)    |
| $P$ for trend             |                |                         | 0.26                 |
| MH (MES < 1)              |                |                         |                      |
| Low (monocyte count < 281/mm$^3$) | 9/29 (31.0)    | 1.00                    | 1.00                 |
| Moderate (281 ≤ monocyte count < 391/mm$^3$) | 10/41 (24.4)   | 0.72 (0.25–2.10)        | 0.88 (0.28–2.77)    |
| High (391/mm$^3$ ≤ monocyte count) | 12/55 (21.8)   | 0.62 (0.23–1.74)        | 0.88 (0.29–2.73)    |
| $P$ for trend             |                |                         | 0.83                 |

ORs were adjusted for age, sex, body mass index, use of prednisolone, use of tumor necrosis factor-α monoclonal antibody, and disease extent. CI, confidence interval; CRP, C-reactive protein; MES, Mayo endoscopic subscore; MH, mucosal healing; OR, odds ratio.
IL-17 also plays a pathological role in UC (23): IL-17A activates various cells including monocytes that release TNF-α, IL-1β, and chemokines (24). The association between proinflammatory cytokines (such as IL-6, IL-17, and TNF-α) and mucosal injury has been reported in patients with UC (25,26). Monocytes that have been activated by proinflammatory cytokines and chemokines might inhibit MH by elevating TNF-α, IL-1β, and chemokines. It remains to be seen whether abnormal peripheral blood monocyte counts are involved in the etiology of UC. In addition, further research is warranted to investigate possible associations between the extracellular matrix, proteases, and peripheral blood monocyte counts in patients with UC.

This study has some limitations. First, because a cross-sectional design was used, we cannot confirm a causal relationship between peripheral blood monocyte count and MH. Second, it is likely that most of the patients in this cohort had been receiving long-term treatment before the study. The long duration of treatment might have affected peripheral blood monocyte counts and endoscopic activity. Third, the possibility of other concurrent collagen diseases that might elevate CRP such as primary sclerosis cholangitis and rheumatoid arthritis was not excluded, and such diseases may have confounded the results. Fourth, CRP was measured using different kits in different patients, hospitals, and periods. In Japan, however, the measurement methods for common laboratory data, including CRP, are standardized, and all common laboratory data in this cohort are quality controlled using standard substances (27). Finally, the subjects of this study were not likely representative of Japanese patients with UC, although the median age, the male-to-female ratio, and the rate of prednisolone use in this study (48.0%, 57.7%, and 19.9%, respectively)

Figure 1. Receiver operating characteristic (ROC) curve showing the usefulness of peripheral blood monocyte count as a marker for complete mucosal healing (MH) in the low C-reactive protein group. The ROC curve for peripheral blood monocyte count as a marker for identifying complete MH had an area under the curve of 0.614. When the cutoff value of peripheral blood monocyte count was set to 285/mm³, the sensitivity and specificity of this marker were 60.0% and 66.1%, respectively.
Inflammatory Bowel Disease

were similar to those in a Japanese national study of 7,907 patients with UC (44.0%, 63.9%, and 15.5%, respectively) (28).

In conclusion, peripheral blood monocyte count may be significantly inversely associated with clinical remission, partial MH, and MH in Japanese patients with UC. In UC patients with low CRP, peripheral blood monocyte count might be significantly inversely associated with only MH. In UC patients with low CRP, therefore, peripheral blood monocyte count might serve as a supplemental blood marker for MH.

Conflicts of Interest
Guarantor of the article: Shinya Furukawa, MD, PhD.
Specific author contributions: Study conception and design: S.F., E.T., Y.I., and Y.H.: Material preparation and data collection: S.F., S.Y., K.S., K.T., Y.H., K.M., T.N., S.S., N.S., H.M., K.O., A.H., H.T., Y.Y., E.T., and Y.I.: Data analysis: S.F. Interpretation of data: S.F., T.M. and Y.I.: First draft writing: S.F. All authors revised and edited drafts and read and approved the final manuscript.
Financial support: None to report.
Potential competing interests: None to report.

Study Highlights

What is known
✓ The number of patients with ulcerative colitis (UC) is increasing.
✓ Mucosal healing (MH) is the therapeutic goal for UC.
✓ Monocytes play an important role in innate immunity.
✓ Some studies have shown an association between peripheral blood monocyte count and disease activity in patients with UC.
✓ The association between peripheral blood monocyte count and MH remains unclear.

What is New Here
✓ Peripheral blood monocyte count is significantly inversely associated with clinical remission, MH, and complete MH in Japanese patients with UC.
✓ In patients with low C-reactive protein, peripheral blood monocyte count might be significantly inversely associated with only MH but not clinical remission.
✓ In patients with high C-reactive protein, no association between peripheral blood monocyte count and clinical outcomes was found.

Acknowledgement
The authors thank Keitarou Kawasaki, Yuji Mizukami, Masayoshi Uraoka, Sanae Nakamura, Satoshi Imamine, Masamoto Torisu, Harumi Yano, Makoto Yano, Masato Murakami, Keiko Kikuchi, Masumi Hino, and Tomo Kogama.

References
1. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.
2. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194–201.
3. Froslie KF, Jahnson J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–22.
4. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010;16:338–46.
5. Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd scientific workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011;5:477–83.
6. Sandborn WJ, Panés J, Zhang H, et al. Correlation between concentrations of fecal calprotectin and outcomes of patients with ulcerative colitis in a phase 2 trial. Gastroenterology 2016;150:96–102.
7. Shah SC, Colombel JF, Sands BE, et al. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:1245–55.e8.
8. Ng SC, Shi HY, Hamid N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2017;390:2769–78.
9. Danese S, Aller M, van Bodegraven AA, et al. Unmet medical needs in ulcerative colitis: An expert group consensus. Dig Dis 2019;37:266–83.
10. Davies JM, Abreu MT. The innate immune system and inflammatory bowel disease. Scand J Gastroenterol 2015;50:24–33.
11. Cherfane CE, Gessel L, Cirillo D, et al. Monocytosis and a low lymphocyte to monocyte ratio are effective biomarkers of ulcerative colitis disease activity. Inflamm Bowel Dis 2015;21:1769–75.
12. Mee AS, Berney J, Jewell DP. Monocytes in inflammatory bowel disease: Absolute monocyte counts. J Clin Pathol 1980;33:917–20.
13. Okba AM, Amin MM, Abdelmoaty AS, et al. Neutrophil/lymphocyte ratio and lymphocyte/monocyte ratio in ulcerative colitis as non-invasive biomarker of disease activity and severity. Auto Immun Highlights 2019;10:4.
14. Anderson A, Cherfane C, Click B, et al. Monocytosis is a biomarker of severity in inflammatory bowel disease: Analysis of a 6-year prospective natural history. Inflamm Bowel Dis 2021. (In press).
15. Xu M, Cen M, Chen X, et al. Correlation between serological biomarker and disease activity in patients with inflammatory bowel disease. Biomed Res Int 2019;2019:6517549.
16. Krzyztek-Kopacka M, Kempsinski R, Bromke M, et al. Biochemical biomarkers of mucosal healing for inflammatory bowel disease in adults. Diagnostics (Basel) 2020;10:367.
17. Shirakishi F, Furukawa S, Yagi S, et al. Serum globulin is associated with endoscopic findings and mucosal healing in Japanese patients with ulcerative colitis. Dig Dis Sci 2021. (In press).
18. Yamamoto M, Saito H, Hara K, et al. Combination of C-reactive protein and monocyte count is a useful prognostic indicator for patients with colorectal cancer. In Vivo 2020;34:299–305.
19. Schroeder KW, Tremaine WJ, Istrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625–9.
20. MacDonald TT, Monteleone I, Fantini MC, et al. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 2011;140:1768–75.
21. Dutta P, Nahrendorf M. Regulation and consequences of monocytosis. Immunol Rev 2014;262:167–78.
22. Panizzi P, Swirski FK, Figueiredo JL, et al. Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytes. J Am Coll Cardiol 2010;55:1629–38.
23. Nanki K, Fujii M, Shimokawa M, et al. Somatic inflammatory gene mutation in human ulcerative colitis epithelium. Nature 2020;577:254–9.
24. Wallace KL, Zheng LB, Kanazawa Y, et al. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014;20:6–21.
25. Scheller J, Garbers C, Rose-John S. Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 2014;26:2–12.
26. Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res 2018;16:26–42.
27. Yamamoto Y, Hosogaya S, Osawa S, et al. Nationwide multicenter study aimed at the establishment of common reference intervals for standardized clinical laboratory tests in Japan. Clin Chem Lab Med 2013;51:1663–72.
28. Matsuoka K, Igarashi A, Sato N, et al. Trends in corticosteroid prescriptions for ulcerative colitis and factors associated with long-term corticosteroid use: Analysis using Japanese claims data from 2006 to 2016. J Crohns Colitis 2021;15:358–66.

Open Access This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.